Peritoneal Cancer - Pipeline Insight, 2026

This “Peritoneal Cancer - Pipeline Insight, 2026” report provides comprehensive insights about 60+ companies and 75+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peritoneal Cancer: Understanding

Peritoneal Cancer: Overview

The infiltration of malignant cells into the serous membrane that lines the abdominal cavity, viscera, and coelom in amniotes is termed peritoneal surface malignancy or peritoneal cancer. This condition is categorized into primary and secondary types. Primary mesothelioma arises from the de novo development of cancer in the mesothelium of the abdomen. In contrast, secondary peritoneal cancer occurs due to the spread of tumor cells from other locations into the peritoneal cavity. Primary peritoneal cancer is further classified based on histology, with terms such as extraovarian primary peritoneal carcinoma (EOPPC), serous surface papillary carcinoma, papillary serous carcinoma of the peritoneum, extraovarian Mullerian adenocarcinoma, and normal-sized ovarian carcinoma syndrome being used to describe this type.

Patients with peritoneal cancer often present with a variety of vague symptoms, including abdominal bloating, distension, nausea, indigestion, anorexia, weight loss, fatigue, constipation, and abdominal or back pain. Among these, abdominal distension and pain are the most commonly reported symptoms, while palpable abdominal mass and ascites are frequent signs.

The pathophysiology of peritoneal cancer involves the spread and growth of tumor cells within the peritoneal cavity. Cancer cells from primary tumors (such as ovarian, colorectal, or gastric cancers) detach and spread into the peritoneal fluid, where they circulate and attach to the peritoneal lining, especially at sites called “milky spots.” The peritoneum provides a favorable environment (“seed and soil” concept) that supports tumor cell survival and growth. These cells adhere to the mesothelium using adhesion molecules and invade deeper tissues by breaking down surrounding structures. Over time, they proliferate, stimulate new blood vessel formation (angiogenesis), and form metastatic deposits. Spread may also occur through lymphatic pathways or during surgical procedures, leading to widespread tumor implantation and progression within the abdominal cavity.

The diagnosis and evaluation of peritoneal cancer require a comprehensive approach combining laboratory tests, imaging, and invasive procedures. Laboratory investigations include complete blood count (CBC), comprehensive metabolic panel (CMP), amylase, lipase, coagulation studies, urinalysis, serum albumin, and blood typing, along with tumor markers such as CA-125, carcinoembryonic antigen (CEA), CA 19-9, alpha-fetoprotein (AFP), and CA 15-3. Imaging plays a central role, with ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), and positron emission tomography (PET-CT) used to detect masses, ascites, peritoneal spread, and metastases. Invasive diagnostic techniques include paracentesis with ascitic fluid analysis (biochemical markers, tumor markers, and cytology), biopsy, laparoscopy, and laparotomy for definitive histopathological confirmation. Additional methods such as immunohistochemistry (IHC) staining (e.g., calretinin, cytokeratin, BerEP4) further aid in tumor characterization.

The treatment of peritoneal cancer involves a multimodal approach combining surgery, chemotherapy, and targeted therapy. The mainstay is cytoreductive surgery (CRS) to remove visible tumors, often followed by hyperthermic intraperitoneal chemotherapy (HIPEC) using agents like mitomycin C, cisplatin, or oxaliplatin to destroy residual disease. Other intraperitoneal therapies include early postoperative intraperitoneal chemotherapy (EPIC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced or unresectable cases. In some patients, bidirectional/neoadjuvant intraperitoneal and systemic chemotherapy (BIPSC/NIPS) is used to reduce tumor burden before surgery. Systemic chemotherapy drugs such as 5-fluorouracil and taxanes are also commonly employed. Additionally, targeted therapies like PARP inhibitors (e.g., olaparib) and emerging immunotherapy options (checkpoint inhibitors) may be used.

"Peritoneal Cancer - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal Cancer pipeline landscape is provided which includes the disease overview and Peritoneal Cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal Cancer.

Peritoneal Cancer Emerging Drugs Chapters

This segment of the Peritoneal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal Cancer Emerging Drugs

• AZD5335: AstraZeneca

AZD5335 is a novel FRα-targeted ADC containing a potent topoisomerase-1 inhibitor (TOP1i) payload (AZ14170132). Topoisomerase-1 (TOP1) removes DNA supercoils and resolves the torsional stress that occurs during DNA transcription and replication. TOP1i specifically and reversibly trap TOP1-DNA cleavage complexes, which leads to replication- and transcription-mediated DNA damage, double-strand DNA breaks, and ultimately, cell death. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Peritoneal Cancer.

• RC88: RemeGen Co., Ltd.

RC88 is a novel antibody drug conjugate (ADC) independently developed by RemeGen targeting mesothelin (MSLN). It uses the company's independently developed innovative bridging technology to connect antibodies and drugs. The structure includes MSLN-targeting antibodies, cleavable connections and a small fraction of cytotoxins (MMAE) can mediate the endocytosis of antibodies by binding to MSLN-positive tumor cells, thereby effectively delivering cytotoxins to cancer cells and achieving improved tumor killing effects. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Peritoneal Cancer.

• Sovilnesib: Volastra Therapeutics, Inc.

Sovilnesib is an orally bioavailable, small-molecule inhibitor of the human kinesin-like protein KIF18A, with potential antineoplastic activity. Upon oral administration, sovilnesib selectively inhibits the activity of KIF18A. This may result in multipolar cell division and inhibit tumor cell proliferation. KIF18A, a mitotic kinesin-8 motor protein, plays an important role in the regulation of chromosome positioning during cell division and is overexpressed in certain cancers. Certain cancer cells with chromosomal instability (CIN) features depend on KIF18A activity for bipolar spindle integrity and cell proliferation. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Peritoneal Cancer.

• BL-M17D1: SystImmune Inc.

BL-M17D1 is a novel antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors, designed with a specialized linker and cytotoxic payload. It acts by binding to HER2 on tumor cells, initiating internalization, and releasing its payload to induce cell death, aiming to treat advanced or metastatic cancers. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Peritoneal Cancer.

Further product details are provided in the report……..

Peritoneal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Peritoneal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peritoneal Cancer

• There are approx. 60+ key companies which are developing the therapies for Peritoneal Cancer. The companies which have their Peritoneal Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Phases

The report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal Cancer drugs.

Peritoneal Cancer Report Insights

• Peritoneal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peritoneal Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peritoneal Cancer drugs?
• How many Peritoneal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peritoneal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peritoneal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• RemeGen Co., Ltd.
• Volastra Therapeutics, Inc.
• SystImmune Inc.
• Instil Bio
• OncoC4, Inc.
• AbbVie
• Rhizen Pharmaceuticals SA
• Toray Industries, Inc
• Precigen, Inc
• Celldex Therapeutics
• Mersana Therapeutics
• Incyte Corporation
• Transgene
• Bio-Path Holdings, Inc.
• Arsenal Biosciences, Inc.
• Novakand Pharma AB
• Regeneron Pharmaceuticals
• Artios Pharma Ltd
• 23andMe, Inc.
• Avenzo Therapeutics, Inc.
• Medicenna Therapeutics, Inc.
• TORL Biotherapeutics, LLC
• CanariaBio Inc.
• Shanghai Jiaolian Drug Research and Development Co., Ltd

Key Products

• AZD5335
• RC88
• Sovilnesib
• BL-M17D1
• ITIL-306
• AI-061
• ABBV-901
• RP12146
• TRK-950
• PRGN-3005
• CDX-585
• XMT-1660
• INCB0123667
• TG4050
• BP1001-A
• AB-1015
• KAND567
• REGN5668
• ART0380
• 23ME-00610
• AVZO-021
• MDNA11
• TORL-1-23
• Oregovomab
• B013

This product will be delivered within 2-4 business days.